<DOC>
	<DOCNO>NCT02347085</DOCNO>
	<brief_summary>Randomized , Phase IIIb , Two-period , Two-treatment Double-blind , Multi-center , Crossover Study Evaluate 24-hour Lung Function Profile Subjects Moderate Very Severe COPD 4 Weeks Treatment PT003 Placebo MDI</brief_summary>
	<brief_title>24-hour Lung Function Subjects With Moderate Very Severe COPD After Treatment With PT003 Placebo MDI</brief_title>
	<detailed_description />
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>At least 40 year age old 80 Screening Women nonchild bear potential negative serum pregnancy test Screening , agree acceptable contraceptive method use consistently correctly Screening 14 day final visit Subjects establish clinical history COPD define American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) Current former smoker history least 10 packyears cigarette smoke Pre postbronchodilator FEV1/FVC ratio &lt; 0.70 Postbronchodilator FEV1 must &lt; 80 % predict normal value , calculate use NHANES III reference equation , measure FEV1 must also ≥750 mL FEV1 &lt; 30 % predict normal value Significant diseases COPD , i.e. , disease condition , opinion Investigator , may put subject risk participation study may influence either result study subject 's ability participate study Women pregnant lactating Subjects , opinion Investigator , current diagnosis asthma Subjects hospitalize due poorly control COPD within 3 month prior Screening Screening Period Subjects poorly control COPD , define acute worsen COPD require treatment oral corticosteroid antibiotic within 6 week prior Screening Screening Period Subjects clinically significant uncontrolled hypertension . Subjects cancer complete remission least five year Subjects abnormal liver function test define AST , ALT , total bilirubin ≥1.5 time upper limit normal Screening repeat test Subjects diagnosis angle closure glaucoma exclude , regardless whether treat . Subjects diagnosis open angle glaucoma intraocular pressure control medication ( ) eligible Subjects symptomatic prostatic hypertrophy clinically significant opinion Investigator . Subjects transurethral resection prostate ( TURP ) full resection prostate within 6 month prior Screening exclude study Subjects bladder neck obstruction urinary retention clinically significant opinion Investigator</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>